Patents by Inventor Nancy Stagliano

Nancy Stagliano has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220098294
    Abstract: The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: April 30, 2021
    Publication date: March 31, 2022
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Patent number: 11028162
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: June 8, 2021
    Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Publication number: 20190211089
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: August 13, 2018
    Publication date: July 11, 2019
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Patent number: 10077300
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: September 18, 2018
    Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Publication number: 20160122425
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: September 14, 2015
    Publication date: May 5, 2016
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Patent number: 9169321
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: October 27, 2015
    Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Publication number: 20140045195
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: July 24, 2013
    Publication date: February 13, 2014
    Applicants: CytomX Therapeutics, Inc., The Regents of the University of California
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Patent number: 8541203
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: September 24, 2013
    Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, James W. West, Jason Sagert
  • Patent number: 8529898
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: September 10, 2013
    Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.
    Inventors: Patrick Sean Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Patent number: 8518404
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: August 27, 2013
    Assignees: The Regents of the University of California, CytomX Therapeutics, Inc.
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare, Jason Sagert
  • Publication number: 20120244154
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 27, 2012
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
  • Publication number: 20120237512
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: March 6, 2012
    Publication date: September 20, 2012
    Inventors: PATRICK DAUGHERTY, NANCY STAGLIANO, JERRY THOMAS, KATHRYN KAMATH, JAMES W. WEST, SANJAY KHARE
  • Publication number: 20120237977
    Abstract: Activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM) are provided. Activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM are provided. Furthermore, ABPs which contain a first TBM, a second TBM and a CM are provided. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. Further provided are libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. Further provided are ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: March 2, 2012
    Publication date: September 20, 2012
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
  • Publication number: 20090304719
    Abstract: The present disclosure provides activatable binding polypeptides (ABPs), which contain a target binding moiety (TBM), a masking moiety (MM), and a cleavable moiety (CM). The present disclosure provides activatable antibody compositions, which contain a TBM containing an antigen binding domain (ABD), a MM and a CM. Furthermore the present disclosure also provides ABPs which contain a first TBM, a second TBM and a CM. The ABPs exhibit an “activatable” conformation such that at least one of the TBMs is less accessible to target when uncleaved than after cleavage of the CM in the presence of a cleaving agent capable of cleaving the CM. The disclosure further provides libraries of candidate ABPs, methods of screening to identify such ABPs, and methods of use. The disclosure further provides ABPs having TBMs that bind VEGF, CTLA-4, or VCAM, ABPs having a first TBM that binds VEGF and a second TBM that binds FGF, as well as compositions and methods of use.
    Type: Application
    Filed: August 21, 2008
    Publication date: December 10, 2009
    Inventors: Patrick Daugherty, Nancy Stagliano, Jerry Thomas, Kathryn Kamath, James W. West, Sanjay Khare
  • Publication number: 20080302732
    Abstract: A fluidic device employs one or more sorting stations for separating target species from other species in a sample. At least one of the sorting stations employs a magnetic field gradient to accomplish separation. In addition, the sorting station is integrated on a single substrate with one or more other modules for processing the sample. For example, the fluidic device may include both a sorting station and a separate trapping station that holds some or all components of the sample for additional processing. The trapping station may be located at a position upstream or downstream from the sorting module.
    Type: Application
    Filed: May 23, 2008
    Publication date: December 11, 2008
    Inventors: Hyongsok Soh, Brian Scott Ferguson, Yanting Zhang, Nancy Stagliano
  • Publication number: 20050037946
    Abstract: The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 and 2419 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease.
    Type: Application
    Filed: January 8, 2004
    Publication date: February 17, 2005
    Inventors: Nancy Stagliano, Aileen Healy, Susan Acton, Katherine Galvin, Mary Donoghue, Amelie Rodrigue-Way, James Tomlinson
  • Publication number: 20030215840
    Abstract: The present invention relates to methods for the diagnosis and treatment of cardiovascular disease, including, but not limited to, atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders. Specifically, the present invention identifies the differential expression of 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 and 6585 genes in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and/or in response to manipulations relevant to cardiovascular disease.
    Type: Application
    Filed: January 29, 2003
    Publication date: November 20, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Thomas J. Logan, Miyoung Chun, Katherine M. Galvin, Aileen Healy, Susan L. Acton, Mary A. Donoghue, Nancy Stagliano, Jacqueline Perodin, Amelie Rodrigue-Way